BRIDGEBIO PHARMA INC (BBIO)
US10806X1028 - Common Stock
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 266.32M | 375.94M | 376.70M | 393.80M | 356.10M | |||
| Marketable Securities | 0.00 | 58.95M | 95.20M | 442.90M | 251.00M | |||
| Other Current Assets | 178.25M | 42.71M | 76.90M | 52.20M | 35.70M | |||
| Total Current Assets | 444.58M | 477.59M | 548.90M | 888.90M | 642.80M | |||
| Non-Current Assets | ||||||||
| PPE Net | 15.14M | 19.84M | 25.20M | 46.00M | 36.80M | |||
| Investments And Advances | 160.44M | 58.95M | N/A | 49.15M | N/A | |||
| Intangibles | 24.52M | 26.32M | 28.70M | 44.90M | N/A | |||
| Other Non-Current Assets | 20.29M | 22.63M | 20.20M | 33.00M | 23.90M | |||
| Total Non-Current Assets | 220.40M | 68.79M | 74.10M | 123.90M | 60.80M | |||
| TOTAL ASSETS | 664.98M | 546.38M | 623.00M | 1.01B | 703.60M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | 300.00K | 1.60M | |||
| Accrued Expenses | 114.08M | 127.09M | 101.70M | 122.90M | 79.60M | |||
| Accounts Payable | 13.36M | 10.65M | 11.60M | 11.90M | 8.90M | |||
| Other Current Liabilities | 11.77M | 6.10M | 8.20M | 0.00 | 5.60M | |||
| Total Current Liabilities | 139.22M | 143.84M | 121.40M | 135.10M | 95.60M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 1.72B | 1.73B | 1.71B | 1.71B | 477.40M | |||
| Other Non-Current Liabilities | 24.84M | 18.34M | 38.90M | 38.30M | 22.60M | |||
| Total Non-Current Liabilities | 1.76B | 1.76B | 1.76B | 1.75B | 550.10M | |||
| TOTAL LIABILITIES | 1.89B | 1.90B | 1.88B | 1.88B | 645.70M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -2.83B | -2.56B | -1.92B | -1.44B | -888.80M | |||
| Additional Paid In Capital | 1.88B | 1.48B | 938.70M | 841.50M | 1.02B | |||
| Minority Interest | 11.53M | 11.72M | 9.70M | 4.80M | 50.00M | |||
| Common Shares | 195.00K | 181.00K | 200.00K | 200.00K | 100.00K | |||
| Treasury Stock | -275.00M | -275.00M | -275.00M | -275.00M | -75.00M | |||
| Other Shareholders' Equity | 5.00K | 31.00K | -300.00K | -100.00K | 200.00K | |||
| Shares Outstanding | 188.99M | 175.08M | 150.60M | 147.30M | 122.80M | |||
| Tangible Book Value per Share | -6.64 | -7.89 | -8.52 | -6.21 | 0.47 | |||
| Total Shareholders' Equity | -1.23B | -1.35B | -1.25B | -870.40M | 57.90M | |||
| TOTAL LIABILITIES AND EQUITY | 664.98M | 546.38M | 623.00M | 1.01B | 703.60M | |||
| Statistics | ||||||||
| Debt/Equity | -1.40 | -1.28 | -1.36 | -1.96 | 8.25 | |||
| Current Ratio | 3.19 | 3.32 | 4.52 | 6.58 | 6.72 | |||
| Return On Assets (ROA) | -66.00% | -117.72% | -77.24% | -55.54% | -63.77% | |||
| Return On Equity (ROE) | N/A | N/A | N/A | N/A | -774.99% | |||
All data in USD , ROIC based on taxRate of 0.21